| HGNC Family | Solute carriers (SLC) |
| Name | solute carrier family 29 (equilibrative nucleoside transporter), member 1 |
| Description | This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq, Jul 2008] |
| Summary |
{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nThe SLC29A1 gene encodes the human equilibrative nucleoside transporter 1 (hENT1), a widely expressed membrane protein responsible for the bidirectional, concentration‐dependent transport of natural nucleosides as well as nucleoside analog drugs. Structural and mutagenesis studies have identified critical transmembrane domains and specific amino acid residues that determine substrate binding, transport activity, and even sensitivity to inhibitors such as dipyridamole. hENT1 not only mediates the cellular uptake of chemotherapeutic agents such as gemcitabine, cytarabine, and ribavirin but is also found in unexpected locations like the mitochondrial membrane—thereby influencing drug toxicity and efficacy. Moreover, reduced hENT1 expression has been linked to treatment resistance in malignancies including pancreatic ductal adenocarcinoma and acute myeloid leukemia, while genetic variations in SLC29A1 modulate both transporter function and clinical chemosensitivity."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "1", "end_ref": "20"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nIn addition to its core function in nucleoside transport, hENT1 exhibits notable tissue‐specific localization and regulation that profoundly affect both normal physiology and pharmacological outcomes. In polarized epithelial cells such as those of the kidney, liver, and placenta, hENT1 is sorted to specific membrane domains to coordinate vectorial transport. Regulatory mechanisms—including promoter polymorphisms, post‐transcriptional modifications, and responses to metabolic stress—modulate hENT1 expression and, consequently, extracellular adenosine levels. These factors have been shown to influence treatment responses across various diseases, with hENT1 expression levels serving as predictive biomarkers for gemcitabine and ribavirin efficacy in cancer and viral disorders."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "21", "end_ref": "32"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nEmerging evidence further expands the role of SLC29A1 beyond conventional nucleoside transport. Novel findings have implicated mutations in SLC29A1 as the genetic basis for the Augustine blood group system—with attendant effects on bone mineral homeostasis—and have linked aberrant hENT1 activity to neurodegenerative disorders such as Huntington's disease. Moreover, pharmacologic modulation of hENT1 by agents like ticagrelor and verapamil, as well as its interplay with metabolic pathways (including glycolysis), provides promising strategies to overcome chemoresistance and improve outcomes in solid tumors. Collectively, these studies underscore hENT1 as a pivotal determinant not only in drug uptake and disposition but also in cellular adaptation to metabolic and ischemic stresses."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "33", "end_ref": "46"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Dhruba J SenGupta, Pek Y Lum, Yurong Lai, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biochemistry (2002)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1021/bi015833w"}], "href": "https://doi.org/10.1021/bi015833w"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11814344"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11814344"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Sylvia Y M Yao, Amy M L Ng, Mark F Vickers, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biol Chem (2002)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1074/jbc.M200966200"}], "href": "https://doi.org/10.1074/jbc.M200966200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12006583"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12006583"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Carlos M Galmarini, Xavier Thomas, Fabien Calvo, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Potential mechanisms of resistance to cytarabine in AML patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Leuk Res (2002)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/s0145-2126(01)00184-9"}], "href": "https://doi.org/10.1016/s0145-2126(01"}, {"type": "t", "text": "00184-9) PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12008078"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12008078"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Yurong Lai, Aimee H Bakken, Jashvant D Unadkat "}, {"type": "b", "children": [{"type": "t", "text": "Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biol Chem (2002)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1074/jbc.M204986200"}], "href": "https://doi.org/10.1074/jbc.M204986200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12097333"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12097333"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Frank Visser, Stephen A Baldwin, R Elwyn Isaac, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Identification and mutational analysis of amino acid residues involved in dipyridamole interactions with human and Caenorhabditis elegans equilibrative nucleoside transporters."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biol Chem (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1074/jbc.M410348200"}], "href": "https://doi.org/10.1074/jbc.M410348200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15649894"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15649894"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "I Hubeek, R W Stam, G J Peters, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Br J Cancer (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.bjc.6602881"}], "href": "https://doi.org/10.1038/sj.bjc.6602881"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16333246"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16333246"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Eun-Woo Lee, Yurong Lai, Huixia Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biol Chem (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1074/jbc.M513825200"}], "href": "https://doi.org/10.1074/jbc.M513825200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16595656"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16595656"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Scott N Myers, Rakesh K Goyal, Jennifer D Roy, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenet Genomics (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/01.fpc.0000189804.41962.15"}], "href": "https://doi.org/10.1097/01.fpc.0000189804.41962.15"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16609362"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16609362"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Marcelo Farías, Rody San Martín, Carlos Puebla, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Physiol (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcp.20680"}], "href": "https://doi.org/10.1002/jcp.20680"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16688763"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16688763"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Silvia Marcé, Míriam Molina-Arcas, Neus Villamor, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Haematologica (2006)"}]}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16818276"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16818276"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "Su-Ryang Kim, Yoshiro Saito, Keiko Maekawa, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1)."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Drug Metab Pharmacokinet (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2133/dmpk.21.248"}], "href": "https://doi.org/10.2133/dmpk.21.248"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16858130"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16858130"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Vijaya L Damaraju, Adam N Elwi, Charlene Hunter, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Am J Physiol Renal Physiol (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1152/ajprenal.00007.2007"}], "href": "https://doi.org/10.1152/ajprenal.00007.2007"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17409283"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17409283"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Tetsuya Oguri, Hiroyuki Achiwa, Hideki Muramatsu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Lett (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.canlet.2007.06.012"}], "href": "https://doi.org/10.1016/j.canlet.2007.06.012"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17658213"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17658213"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "D Santini, G Perrone, B Vincenzi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Ann Oncol (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/annonc/mdm576"}], "href": "https://doi.org/10.1093/annonc/mdm576"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18187485"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18187485"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "Rajgopal Govindarajan, Christopher J Endres, Dale Whittington, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Am J Physiol Gastrointest Liver Physiol (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1152/ajpgi.00542.2007"}], "href": "https://doi.org/10.1152/ajpgi.00542.2007"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18635603"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18635603"}]}, {"type": "r", "ref": 16, "children": [{"type": "t", "text": "C Escudero, P Casanello, L Sobrevia "}, {"type": "b", "children": [{"type": "t", "text": "Human equilibrative nucleoside transporters 1 and 2 may be differentially modulated by A2B adenosine receptors in placenta microvascular endothelial cells from pre-eclampsia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Placenta (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.placenta.2008.06.014"}], "href": "https://doi.org/10.1016/j.placenta.2008.06.014"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18703227"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18703227"}]}, {"type": "r", "ref": 17, "children": [{"type": "t", "text": "Christopher J Endres, Aaron M Moss, Ban Ke, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Pharmacol Exp Ther (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1124/jpet.108.145854"}], "href": "https://doi.org/10.1124/jpet.108.145854"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19164463"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19164463"}]}, {"type": "r", "ref": 18, "children": [{"type": "t", "text": "Raphaël Maréchal, John R Mackey, Raymond Lai, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Cancer Res (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1078-0432.CCR-08-2080"}], "href": "https://doi.org/10.1158/1078-0432.CCR-08-2080"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19318496"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19318496"}]}, {"type": "r", "ref": 19, "children": [{"type": "t", "text": "Takahiro Yamauchi, Eiju Negoro, Shinji Kishi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biochem Pharmacol (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.bcp.2009.03.011"}], "href": "https://doi.org/10.1016/j.bcp.2009.03.011"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19428333"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19428333"}]}, {"type": "r", "ref": 20, "children": [{"type": "t", "text": "Guilan Jin, Hiromichi Matsushita, Satomi Asai, et al. "}, {"type": "b", "children": [{"type": "t", "text": "FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biochem Biophys Res Commun (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.bbrc.2009.10.094"}], "href": "https://doi.org/10.1016/j.bbrc.2009.10.094"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19853583"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19853583"}]}, {"type": "r", "ref": 21, "children": [{"type": "t", "text": "Taro Okazaki, Milind Javle, Motofumi Tanaka, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Cancer Res (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1078-0432.CCR-09-1555"}], "href": "https://doi.org/10.1158/1078-0432.CCR-09-1555"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20028759"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20028759"}]}, {"type": "r", "ref": 22, "children": [{"type": "t", "text": "Marcelo Farías, Carlos Puebla, Francisco Westermeier, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPalpha in human umbilical vein endothelial cells from gestational diabetes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cardiovasc Res (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/cvr/cvp410"}], "href": "https://doi.org/10.1093/cvr/cvp410"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20032083"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20032083"}]}, {"type": "r", "ref": 23, "children": [{"type": "t", "text": "Yukina Fukuchi, Tomomi Furihata, Misato Hashizume, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Characterization of ribavirin uptake systems in human hepatocytes."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Hepatol (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.jhep.2010.01.011"}], "href": "https://doi.org/10.1016/j.jhep.2010.01.011"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20185188"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20185188"}]}, {"type": "r", "ref": 24, "children": [{"type": "t", "text": "Natalia Gass, Hanna M Ollila, Siddheshwar Utge, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Contribution of adenosine related genes to the risk of depression with disturbed sleep."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Affect Disord (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.jad.2010.03.009"}], "href": "https://doi.org/10.1016/j.jad.2010.03.009"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20392501"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20392501"}]}, {"type": "r", "ref": 25, "children": [{"type": "t", "text": "Emiko Sugiyama, Nahoko Kaniwa, Su-Ryang Kim, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacokinet (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2165/11532970-000000000-00000"}], "href": "https://doi.org/10.2165/11532970-000000000-00000"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20608756"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20608756"}]}, {"type": "r", "ref": 26, "children": [{"type": "t", "text": "Motofumi Tanaka, Milind Javle, Xiaoqun Dong, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/cncr.25282"}], "href": "https://doi.org/10.1002/cncr.25282"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20665488"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20665488"}]}, {"type": "r", "ref": 27, "children": [{"type": "t", "text": "Robert J Paproski, Melinda Wuest, Hans-Sonke Jans, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Nucl Med (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2967/jnumed.110.076356"}], "href": "https://doi.org/10.2967/jnumed.110.076356"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20720035"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20720035"}]}, {"type": "r", "ref": 28, "children": [{"type": "t", "text": "Judit Morello, Lorena Cuenca, Vincent Soriano, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Infect Dis (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1086/656334"}], "href": "https://doi.org/10.1086/656334"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20812847"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20812847"}]}, {"type": "r", "ref": 29, "children": [{"type": "t", "text": "Richard Kim, Ann Tan, Kevin K Lai, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/cncr.25883"}], "href": "https://doi.org/10.1002/cncr.25883"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21264835"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21264835"}]}, {"type": "r", "ref": 30, "children": [{"type": "t", "text": "Sylvia Y M Yao, Amy M L Ng, Carol E Cass, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1)."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biol Chem (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1074/jbc.M111.236117"}], "href": "https://doi.org/10.1074/jbc.M111.236117"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21795683"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21795683"}]}, {"type": "r", "ref": 31, "children": [{"type": "t", "text": "Akihito Tsubota, Noritomo Shimada, Kai Yoshizawa, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Liver Int (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/j.1478-3231.2011.02727.x"}], "href": "https://doi.org/10.1111/j.1478-3231.2011.02727.x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22212648"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22212648"}]}, {"type": "r", "ref": 32, "children": [{"type": "t", "text": "Raphaël Maréchal, Jean-Baptiste Bachet, John R Mackey, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Gastroenterology (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1053/j.gastro.2012.06.006"}], "href": "https://doi.org/10.1053/j.gastro.2012.06.006"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22705007"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22705007"}]}, {"type": "r", "ref": 33, "children": [{"type": "t", "text": "K Eto, H Kawakami, M Kuwatani, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Br J Cancer (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/bjc.2013.108"}], "href": "https://doi.org/10.1038/bjc.2013.108"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23492684"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23492684"}]}, {"type": "r", "ref": 34, "children": [{"type": "t", "text": "Michael A Zimmerman, Eunyoung Tak, Stefan F Ehrentraut, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Equilibrative nucleoside transporter (ENT)-1-dependent elevation of extracellular adenosine protects the liver during ischemia and reperfusion."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hepatology (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/hep.26505"}], "href": "https://doi.org/10.1002/hep.26505"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23703920"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23703920"}]}, {"type": "r", "ref": 35, "children": [{"type": "t", "text": "Christina H Wei, Tristan R Gorgan, David A Elashoff, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pancreas (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/MPA.0b013e3182a23ae4"}], "href": "https://doi.org/10.1097/MPA.0b013e3182a23ae4"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24152955"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24152955"}]}, {"type": "r", "ref": 36, "children": [{"type": "t", "text": "Soo-Youn Lee, Seock-Ah Im, Yeon Hee Park, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Eur J Cancer (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.ejca.2013.11.028"}], "href": "https://doi.org/10.1016/j.ejca.2013.11.028"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24361227"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24361227"}]}, {"type": "r", "ref": 37, "children": [{"type": "t", "text": "Geoff Daniels, Bryan A Ballif, Virginie Helias, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2015-03-631598"}], "href": "https://doi.org/10.1182/blood-2015-03-631598"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25896650"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25896650"}]}, {"type": "r", "ref": 38, "children": [{"type": "t", "text": "Matthew L Diamond, Anne C Ritter, Edwin K Jackson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Epilepsia (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/epi.13044"}], "href": "https://doi.org/10.1111/epi.13044"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26040919"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26040919"}]}, {"type": "r", "ref": 39, "children": [{"type": "t", "text": "Ajay Abraham, Savitha Varatharajan, Sreeja Karathedath, et al. "}, {"type": "b", "children": [{"type": "t", "text": "RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenomics (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2217/pgs.15.44"}], "href": "https://doi.org/10.2217/pgs.15.44"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26083014"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26083014"}]}, {"type": "r", "ref": 40, "children": [{"type": "t", "text": "Lu Zhao, Yue Zhao, Bettina Schwarz, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Oncol (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/ijo.2016.3512"}], "href": "https://doi.org/10.3892/ijo.2016.3512"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "27177126"}], "href": "https://pubmed.ncbi.nlm.nih.gov/27177126"}]}, {"type": "r", "ref": 41, "children": [{"type": "t", "text": "Rachel A Hesler, Jennifer J Huang, Mark D Starr, et al. "}, {"type": "b", "children": [{"type": "t", "text": "TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/bgw093"}], "href": "https://doi.org/10.1093/carcin/bgw093"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "27604902"}], "href": "https://pubmed.ncbi.nlm.nih.gov/27604902"}]}, {"type": "r", "ref": 42, "children": [{"type": "t", "text": "Riyaad Aungraheeta, Alexandra Conibear, Mark Butler, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2016-03-707844"}], "href": "https://doi.org/10.1182/blood-2016-03-707844"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "27694321"}], "href": "https://pubmed.ncbi.nlm.nih.gov/27694321"}]}, {"type": "r", "ref": 43, "children": [{"type": "t", "text": "Yu-Han Kao, Meng-Syuan Lin, Chiung-Mei Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Targeting ENT1 and adenosine tone for the treatment of Huntington's disease."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Hum Mol Genet (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/hmg/ddw402"}], "href": "https://doi.org/10.1093/hmg/ddw402"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28069792"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28069792"}]}, {"type": "r", "ref": 44, "children": [{"type": "t", "text": "Anren Song, Yujin Zhang, Leng Han, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Erythrocytes retain hypoxic adenosine response for faster acclimatization upon re-ascent."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Commun (2017)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/ncomms14108"}], "href": "https://doi.org/10.1038/ncomms14108"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28169986"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28169986"}]}, {"type": "r", "ref": 45, "children": [{"type": "t", "text": "Nicholas J Wright, Seok-Yong Lee "}, {"type": "b", "children": [{"type": "t", "text": "Structures of human ENT1 in complex with adenosine reuptake inhibitors."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Struct Mol Biol (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41594-019-0245-7"}], "href": "https://doi.org/10.1038/s41594-019-0245-7"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31235912"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31235912"}]}, {"type": "r", "ref": 46, "children": [{"type": "t", "text": "Yun Xi, Peng Yuan, Ting Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Lett (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.canlet.2020.03.015"}], "href": "https://doi.org/10.1016/j.canlet.2020.03.015"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32200037"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32200037"}]}]}]}
|
| Synonyms | ENT1 |
| Proteins | S29A1_HUMAN |
| NCBI Gene ID | 2030 |
| API | |
| Download Associations | |
| Predicted Functions |
![]() |
| Co-expressed Genes |
![]() |
| Expression in Tissues and Cell Lines |
![]() |
SLC29A1 has 8,957 functional associations with biological entities spanning 9 categories (molecular profile, organism, chemical, functional term, phrase or reference, disease, phenotype or trait, structural feature, cell line, cell type or tissue, gene, protein or microRNA, sequence feature) extracted from 126 datasets.
Click the + buttons to view associations for SLC29A1 from the datasets below.
If available, associations are ranked by standardized value
| Dataset | Summary | |
|---|---|---|
| Allen Brain Atlas Adult Human Brain Tissue Gene Expression Profiles | tissues with high or low expression of SLC29A1 gene relative to other tissues from the Allen Brain Atlas Adult Human Brain Tissue Gene Expression Profiles dataset. | |
| Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles | tissues with high or low expression of SLC29A1 gene relative to other tissues from the Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles dataset. | |
| Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of SLC29A1 gene relative to other tissue samples from the Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles dataset. | |
| Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray | tissue samples with high or low expression of SLC29A1 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray dataset. | |
| Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by RNA-seq | tissue samples with high or low expression of SLC29A1 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by RNA-seq dataset. | |
| Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles | tissues with high or low expression of SLC29A1 gene relative to other tissues from the Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles dataset. | |
| BioGPS Cell Line Gene Expression Profiles | cell lines with high or low expression of SLC29A1 gene relative to other cell lines from the BioGPS Cell Line Gene Expression Profiles dataset. | |
| BioGPS Human Cell Type and Tissue Gene Expression Profiles | cell types and tissues with high or low expression of SLC29A1 gene relative to other cell types and tissues from the BioGPS Human Cell Type and Tissue Gene Expression Profiles dataset. | |
| BioGPS Mouse Cell Type and Tissue Gene Expression Profiles | cell types and tissues with high or low expression of SLC29A1 gene relative to other cell types and tissues from the BioGPS Mouse Cell Type and Tissue Gene Expression Profiles dataset. | |
| CCLE Cell Line Gene CNV Profiles | cell lines with high or low copy number of SLC29A1 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset. | |
| CCLE Cell Line Gene Expression Profiles | cell lines with high or low expression of SLC29A1 gene relative to other cell lines from the CCLE Cell Line Gene Expression Profiles dataset. | |
| CCLE Cell Line Gene Mutation Profiles | cell lines with SLC29A1 gene mutations from the CCLE Cell Line Gene Mutation Profiles dataset. | |
| CCLE Cell Line Proteomics | Cell lines associated with SLC29A1 protein from the CCLE Cell Line Proteomics dataset. | |
| CellMarker Gene-Cell Type Associations | cell types associated with SLC29A1 gene from the CellMarker Gene-Cell Type Associations dataset. | |
| ChEA Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of SLC29A1 gene from the CHEA Transcription Factor Binding Site Profiles dataset. | |
| ChEA Transcription Factor Targets | transcription factors binding the promoter of SLC29A1 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset. | |
| ChEA Transcription Factor Targets 2022 | transcription factors binding the promoter of SLC29A1 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets 2022 dataset. | |
| CMAP Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of SLC29A1 gene from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| COMPARTMENTS Curated Protein Localization Evidence Scores | cellular components containing SLC29A1 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset. | |
| COMPARTMENTS Curated Protein Localization Evidence Scores 2025 | cellular components containing SLC29A1 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores 2025 dataset. | |
| COMPARTMENTS Experimental Protein Localization Evidence Scores | cellular components containing SLC29A1 protein in low- or high-throughput protein localization assays from the COMPARTMENTS Experimental Protein Localization Evidence Scores dataset. | |
| COMPARTMENTS Text-mining Protein Localization Evidence Scores | cellular components co-occuring with SLC29A1 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset. | |
| COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 | cellular components co-occuring with SLC29A1 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 dataset. | |
| COSMIC Cell Line Gene CNV Profiles | cell lines with high or low copy number of SLC29A1 gene relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset. | |
| COSMIC Cell Line Gene Mutation Profiles | cell lines with SLC29A1 gene mutations from the COSMIC Cell Line Gene Mutation Profiles dataset. | |
| CTD Gene-Chemical Interactions | chemicals interacting with SLC29A1 gene/protein from the curated CTD Gene-Chemical Interactions dataset. | |
| CTD Gene-Disease Associations | diseases associated with SLC29A1 gene/protein from the curated CTD Gene-Disease Associations dataset. | |
| DeepCoverMOA Drug Mechanisms of Action | small molecule perturbations with high or low expression of SLC29A1 protein relative to other small molecule perturbations from the DeepCoverMOA Drug Mechanisms of Action dataset. | |
| DepMap CRISPR Gene Dependency | cell lines with fitness changed by SLC29A1 gene knockdown relative to other cell lines from the DepMap CRISPR Gene Dependency dataset. | |
| DISEASES Experimental Gene-Disease Association Evidence Scores 2025 | diseases associated with SLC29A1 gene in GWAS datasets from the DISEASES Experimental Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores | diseases co-occuring with SLC29A1 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores dataset. | |
| DISEASES Text-mining Gene-Disease Association Evidence Scores 2025 | diseases co-occuring with SLC29A1 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores 2025 dataset. | |
| DisGeNET Gene-Disease Associations | diseases associated with SLC29A1 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset. | |
| DisGeNET Gene-Phenotype Associations | phenotypes associated with SLC29A1 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Phenoptype Associations dataset. | |
| DrugBank Drug Targets | interacting drugs for SLC29A1 protein from the curated DrugBank Drug Targets dataset. | |
| ENCODE Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at SLC29A1 gene from the ENCODE Histone Modification Site Profiles dataset. | |
| ENCODE Transcription Factor Binding Site Profiles | transcription factor binding site profiles with transcription factor binding evidence at the promoter of SLC29A1 gene from the ENCODE Transcription Factor Binding Site Profiles dataset. | |
| ENCODE Transcription Factor Targets | transcription factors binding the promoter of SLC29A1 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset. | |
| ESCAPE Omics Signatures of Genes and Proteins for Stem Cells | PubMedIDs of publications reporting gene signatures containing SLC29A1 from the ESCAPE Omics Signatures of Genes and Proteins for Stem Cells dataset. | |
| GAD Gene-Disease Associations | diseases associated with SLC29A1 gene in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset. | |
| GAD High Level Gene-Disease Associations | diseases associated with SLC29A1 gene in GWAS and other genetic association datasets from the GAD High Level Gene-Disease Associations dataset. | |
| GDSC Cell Line Gene Expression Profiles | cell lines with high or low expression of SLC29A1 gene relative to other cell lines from the GDSC Cell Line Gene Expression Profiles dataset. | |
| GeneRIF Biological Term Annotations | biological terms co-occuring with SLC29A1 gene in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset. | |
| GeneSigDB Published Gene Signatures | PubMedIDs of publications reporting gene signatures containing SLC29A1 from the GeneSigDB Published Gene Signatures dataset. | |
| GEO Signatures of Differentially Expressed Genes for Diseases | disease perturbations changing expression of SLC29A1 gene from the GEO Signatures of Differentially Expressed Genes for Diseases dataset. | |
| GEO Signatures of Differentially Expressed Genes for Gene Perturbations | gene perturbations changing expression of SLC29A1 gene from the GEO Signatures of Differentially Expressed Genes for Gene Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Kinase Perturbations | kinase perturbations changing expression of SLC29A1 gene from the GEO Signatures of Differentially Expressed Genes for Kinase Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of SLC29A1 gene from the GEO Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| GEO Signatures of Differentially Expressed Genes for Transcription Factor Perturbations | transcription factor perturbations changing expression of SLC29A1 gene from the GEO Signatures of Differentially Expressed Genes for Transcription Factor Perturbations dataset. | |
| GEO Signatures of Differentially Expressed Genes for Viral Infections | virus perturbations changing expression of SLC29A1 gene from the GEO Signatures of Differentially Expressed Genes for Viral Infections dataset. | |
| GlyGen Glycosylated Proteins | ligands (chemical) binding SLC29A1 protein from the GlyGen Glycosylated Proteins dataset. | |
| GO Biological Process Annotations 2015 | biological processes involving SLC29A1 gene from the curated GO Biological Process Annotations 2015 dataset. | |
| GO Biological Process Annotations 2023 | biological processes involving SLC29A1 gene from the curated GO Biological Process Annotations 2023 dataset. | |
| GO Biological Process Annotations 2025 | biological processes involving SLC29A1 gene from the curated GO Biological Process Annotations2025 dataset. | |
| GO Cellular Component Annotations 2015 | cellular components containing SLC29A1 protein from the curated GO Cellular Component Annotations 2015 dataset. | |
| GO Cellular Component Annotations 2023 | cellular components containing SLC29A1 protein from the curated GO Cellular Component Annotations 2023 dataset. | |
| GO Cellular Component Annotations 2025 | cellular components containing SLC29A1 protein from the curated GO Cellular Component Annotations 2025 dataset. | |
| GO Molecular Function Annotations 2015 | molecular functions performed by SLC29A1 gene from the curated GO Molecular Function Annotations 2015 dataset. | |
| GO Molecular Function Annotations 2023 | molecular functions performed by SLC29A1 gene from the curated GO Molecular Function Annotations 2023 dataset. | |
| GO Molecular Function Annotations 2025 | molecular functions performed by SLC29A1 gene from the curated GO Molecular Function Annotations 2025 dataset. | |
| GTEx eQTL 2025 | SNPs regulating expression of SLC29A1 gene from the GTEx eQTL 2025 dataset. | |
| GTEx Tissue Gene Expression Profiles | tissues with high or low expression of SLC29A1 gene relative to other tissues from the GTEx Tissue Gene Expression Profiles dataset. | |
| GTEx Tissue Gene Expression Profiles 2023 | tissues with high or low expression of SLC29A1 gene relative to other tissues from the GTEx Tissue Gene Expression Profiles 2023 dataset. | |
| GTEx Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of SLC29A1 gene relative to other tissue samples from the GTEx Tissue Sample Gene Expression Profiles dataset. | |
| Guide to Pharmacology Chemical Ligands of Receptors | ligands (chemical) binding SLC29A1 receptor from the curated Guide to Pharmacology Chemical Ligands of Receptors dataset. | |
| GWAS Catalog SNP-Phenotype Associations 2025 | phenotypes associated with SLC29A1 gene in GWAS datasets from the GWAS Catalog SNP-Phenotype Associations 2025 dataset. | |
| GWASdb SNP-Disease Associations | diseases associated with SLC29A1 gene in GWAS and other genetic association datasets from the GWASdb SNP-Disease Associations dataset. | |
| GWASdb SNP-Phenotype Associations | phenotypes associated with SLC29A1 gene in GWAS datasets from the GWASdb SNP-Phenotype Associations dataset. | |
| Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles | cell lines with high or low expression of SLC29A1 gene relative to other cell lines from the Heiser et al., PNAS, 2011 Cell Line Gene Expression Profiles dataset. | |
| HMDB Metabolites of Enzymes | interacting metabolites for SLC29A1 protein from the curated HMDB Metabolites of Enzymes dataset. | |
| HPA Cell Line Gene Expression Profiles | cell lines with high or low expression of SLC29A1 gene relative to other cell lines from the HPA Cell Line Gene Expression Profiles dataset. | |
| HPA Tissue Gene Expression Profiles | tissues with high or low expression of SLC29A1 gene relative to other tissues from the HPA Tissue Gene Expression Profiles dataset. | |
| HPA Tissue Protein Expression Profiles | tissues with high or low expression of SLC29A1 protein relative to other tissues from the HPA Tissue Protein Expression Profiles dataset. | |
| HPA Tissue Sample Gene Expression Profiles | tissue samples with high or low expression of SLC29A1 gene relative to other tissue samples from the HPA Tissue Sample Gene Expression Profiles dataset. | |
| Hub Proteins Protein-Protein Interactions | interacting hub proteins for SLC29A1 from the curated Hub Proteins Protein-Protein Interactions dataset. | |
| HuGE Navigator Gene-Phenotype Associations | phenotypes associated with SLC29A1 gene by text-mining GWAS publications from the HuGE Navigator Gene-Phenotype Associations dataset. | |
| IMPC Knockout Mouse Phenotypes | phenotypes of mice caused by SLC29A1 gene knockout from the IMPC Knockout Mouse Phenotypes dataset. | |
| InterPro Predicted Protein Domain Annotations | protein domains predicted for SLC29A1 protein from the InterPro Predicted Protein Domain Annotations dataset. | |
| JASPAR Predicted Human Transcription Factor Targets 2025 | transcription factors regulating expression of SLC29A1 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Human Transcription Factor Targets dataset. | |
| JASPAR Predicted Mouse Transcription Factor Targets 2025 | transcription factors regulating expression of SLC29A1 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Mouse Transcription Factor Targets 2025 dataset. | |
| JASPAR Predicted Transcription Factor Targets | transcription factors regulating expression of SLC29A1 gene predicted using known transcription factor binding site motifs from the JASPAR Predicted Transcription Factor Targets dataset. | |
| Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles | cell lines with high or low copy number of SLC29A1 gene relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset. | |
| Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles | cell lines with high or low expression of SLC29A1 gene relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles dataset. | |
| Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles | cell lines with SLC29A1 gene mutations from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles dataset. | |
| KnockTF Gene Expression Profiles with Transcription Factor Perturbations | transcription factor perturbations changing expression of SLC29A1 gene from the KnockTF Gene Expression Profiles with Transcription Factor Perturbations dataset. | |
| LINCS L1000 CMAP Chemical Perturbation Consensus Signatures | small molecule perturbations changing expression of SLC29A1 gene from the LINCS L1000 CMAP Chemical Perturbations Consensus Signatures dataset. | |
| LINCS L1000 CMAP CRISPR Knockout Consensus Signatures | gene perturbations changing expression of SLC29A1 gene from the LINCS L1000 CMAP CRISPR Knockout Consensus Signatures dataset. | |
| LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules | small molecule perturbations changing expression of SLC29A1 gene from the LINCS L1000 CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset. | |
| LOCATE Curated Protein Localization Annotations | cellular components containing SLC29A1 protein in low- or high-throughput protein localization assays from the LOCATE Curated Protein Localization Annotations dataset. | |
| LOCATE Predicted Protein Localization Annotations | cellular components predicted to contain SLC29A1 protein from the LOCATE Predicted Protein Localization Annotations dataset. | |
| MGI Mouse Phenotype Associations 2023 | phenotypes of transgenic mice caused by SLC29A1 gene mutations from the MGI Mouse Phenotype Associations 2023 dataset. | |
| MiRTarBase microRNA Targets | microRNAs targeting SLC29A1 gene in low- or high-throughput microRNA targeting studies from the MiRTarBase microRNA Targets dataset. | |
| MotifMap Predicted Transcription Factor Targets | transcription factors regulating expression of SLC29A1 gene predicted using known transcription factor binding site motifs from the MotifMap Predicted Transcription Factor Targets dataset. | |
| MoTrPAC Rat Endurance Exercise Training | tissue samples with high or low expression of SLC29A1 gene relative to other tissue samples from the MoTrPAC Rat Endurance Exercise Training dataset. | |
| MPO Gene-Phenotype Associations | phenotypes of transgenic mice caused by SLC29A1 gene mutations from the MPO Gene-Phenotype Associations dataset. | |
| MSigDB Signatures of Differentially Expressed Genes for Cancer Gene Perturbations | gene perturbations changing expression of SLC29A1 gene from the MSigDB Signatures of Differentially Expressed Genes for Cancer Gene Perturbations dataset. | |
| NIBR DRUG-seq U2OS MoA Box Gene Expression Profiles | drug perturbations changing expression of SLC29A1 gene from the NIBR DRUG-seq U2OS MoA Box dataset. | |
| Pathway Commons Protein-Protein Interactions | interacting proteins for SLC29A1 from the Pathway Commons Protein-Protein Interactions dataset. | |
| PerturbAtlas Signatures of Differentially Expressed Genes for Gene Perturbations | gene perturbations changing expression of SLC29A1 gene from the PerturbAtlas Signatures of Differentially Expressed Genes for Gene Perturbations dataset. | |
| PerturbAtlas Signatures of Differentially Expressed Genes for Mouse Gene Perturbations | gene perturbations changing expression of SLC29A1 gene from the PerturbAtlas Signatures of Differentially Expressed Genes for Gene Perturbations dataset. | |
| PFOCR Pathway Figure Associations 2023 | pathways involving SLC29A1 protein from the PFOCR Pathway Figure Associations 2023 dataset. | |
| PFOCR Pathway Figure Associations 2024 | pathways involving SLC29A1 protein from the Wikipathways PFOCR 2024 dataset. | |
| Phosphosite Textmining Biological Term Annotations | biological terms co-occuring with SLC29A1 protein in abstracts of publications describing phosphosites from the Phosphosite Textmining Biological Term Annotations dataset. | |
| PhosphoSitePlus Substrates of Kinases | kinases that phosphorylate SLC29A1 protein from the curated PhosphoSitePlus Substrates of Kinases dataset. | |
| Reactome Pathways 2014 | pathways involving SLC29A1 protein from the Reactome Pathways dataset. | |
| Reactome Pathways 2024 | pathways involving SLC29A1 protein from the Reactome Pathways 2024 dataset. | |
| Replogle et al., Cell, 2022 K562 Essential Perturb-seq Gene Perturbation Signatures | gene perturbations changing expression of SLC29A1 gene from the Replogle et al., Cell, 2022 K562 Essential Perturb-seq Gene Perturbation Signatures dataset. | |
| Replogle et al., Cell, 2022 K562 Genome-wide Perturb-seq Gene Perturbation Signatures | gene perturbations changing expression of SLC29A1 gene from the Replogle et al., Cell, 2022 K562 Genome-wide Perturb-seq Gene Perturbation Signatures dataset. | |
| Roadmap Epigenomics Cell and Tissue DNA Methylation Profiles | cell types and tissues with high or low DNA methylation of SLC29A1 gene relative to other cell types and tissues from the Roadmap Epigenomics Cell and Tissue DNA Methylation Profiles dataset. | |
| Roadmap Epigenomics Cell and Tissue Gene Expression Profiles | cell types and tissues with high or low expression of SLC29A1 gene relative to other cell types and tissues from the Roadmap Epigenomics Cell and Tissue Gene Expression Profiles dataset. | |
| Roadmap Epigenomics Histone Modification Site Profiles | histone modification site profiles with high histone modification abundance at SLC29A1 gene from the Roadmap Epigenomics Histone Modification Site Profiles dataset. | |
| RummaGEO Drug Perturbation Signatures | drug perturbations changing expression of SLC29A1 gene from the RummaGEO Drug Perturbation Signatures dataset. | |
| RummaGEO Gene Perturbation Signatures | gene perturbations changing expression of SLC29A1 gene from the RummaGEO Gene Perturbation Signatures dataset. | |
| Sanger Dependency Map Cancer Cell Line Proteomics | cell lines associated with SLC29A1 protein from the Sanger Dependency Map Cancer Cell Line Proteomics dataset. | |
| SynGO Synaptic Gene Annotations | synaptic terms associated with SLC29A1 gene from the SynGO Synaptic Gene Annotations dataset. | |
| TargetScan Predicted Conserved microRNA Targets | microRNAs regulating expression of SLC29A1 gene predicted using conserved miRNA seed sequences from the TargetScan Predicted Conserved microRNA Targets dataset. | |
| TargetScan Predicted Nonconserved microRNA Targets | microRNAs regulating expression of SLC29A1 gene predicted using nonconserved miRNA seed sequences from the TargetScan Predicted Nonconserved microRNA Targets dataset. | |
| TCGA Signatures of Differentially Expressed Genes for Tumors | tissue samples with high or low expression of SLC29A1 gene relative to other tissue samples from the TCGA Signatures of Differentially Expressed Genes for Tumors dataset. | |
| TISSUES Curated Tissue Protein Expression Evidence Scores | tissues with high expression of SLC29A1 protein from the TISSUES Curated Tissue Protein Expression Evidence Scores dataset. | |
| TISSUES Curated Tissue Protein Expression Evidence Scores 2025 | tissues with high expression of SLC29A1 protein from the TISSUES Curated Tissue Protein Expression Evidence Scores 2025 dataset. | |
| TISSUES Experimental Tissue Protein Expression Evidence Scores | tissues with high expression of SLC29A1 protein in proteomics datasets from the TISSUES Experimental Tissue Protein Expression Evidence Scores dataset. | |
| TISSUES Experimental Tissue Protein Expression Evidence Scores 2025 | tissues with high expression of SLC29A1 protein in proteomics datasets from the TISSUES Experimental Tissue Protein Expression Evidence Scores 2025 dataset. | |
| TISSUES Text-mining Tissue Protein Expression Evidence Scores | tissues co-occuring with SLC29A1 protein in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores dataset. | |
| TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 | tissues co-occuring with SLC29A1 protein in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 dataset. | |
| WikiPathways Pathways 2014 | pathways involving SLC29A1 protein from the Wikipathways Pathways 2014 dataset. | |
| WikiPathways Pathways 2024 | pathways involving SLC29A1 protein from the WikiPathways Pathways 2024 dataset. | |